Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Human pericardial macrophages suppress cardiac fibrosis through cystatin C signaling after myocardial infarction
Ali Fatehi Hassanabad, Sarthak Sinha, Arzina Jaffer, Darrell Belke, Nicole L. Rosin, Elodie Labit, Daniel Young, Friederike I. Schoettler, Keerthana Chockalingam, Benjamin Haeyul Lee, Jameson A. Dundas, Emilie de Chantal, Carmina A. Isidoro, Alexander Tam, Hanjoo B. Shim, Anna N. Zarzycki, Afshin Derakhshani, Elisabeth Gorgiogianni, Jeannine D. Turnbull, Antoine Dufour, Shalina S. Ousman, Jeff A. Biernaskie, Paul W.M. Fedak, Justin F. Deniset
Ali Fatehi Hassanabad, Sarthak Sinha, Arzina Jaffer, Darrell Belke, Nicole L. Rosin, Elodie Labit, Daniel Young, Friederike I. Schoettler, Keerthana Chockalingam, Benjamin Haeyul Lee, Jameson A. Dundas, Emilie de Chantal, Carmina A. Isidoro, Alexander Tam, Hanjoo B. Shim, Anna N. Zarzycki, Afshin Derakhshani, Elisabeth Gorgiogianni, Jeannine D. Turnbull, Antoine Dufour, Shalina S. Ousman, Jeff A. Biernaskie, Paul W.M. Fedak, Justin F. Deniset
View: Text | PDF
Research Article Cardiology Inflammation

Human pericardial macrophages suppress cardiac fibrosis through cystatin C signaling after myocardial infarction

  • Text
  • PDF
Abstract

The pericardium plays an important homeostatic role for the neighboring heart, providing both lubrication and structural support. In vivo models have further identified a protective role for the pericardium in modulating cardiac remodeling following myocardial infarction, possibly through the actions of tissue-resident pericardial macrophages. Using patient-derived pericardial samples, we establish that human pericardial immune cells directly inhibit cardiac fibroblast fibrotic activity, and this action is dampened following myocardial infarction. Using single-cell RNA sequencing of patient pericardial fluid cells, we identify two pericardial macrophage subsets that are uniquely altered in response to myocardial infarction, which contributes to a shift in their effector molecule expression profiles. We confirm that fibronectin-expressing human pericardial macrophages are the primary driver of the pericardial antifibrotic actions through the release of cystatin C. Finally, we establish cystatin C as a myeloid cell–derived cardioprotective effector molecule in an in vivo model of myocardial infarction. Collectively, we uncover a molecular mechanism of the local immune environment that regulates cardiac remodeling after myocardial infarction.

Authors

Ali Fatehi Hassanabad, Sarthak Sinha, Arzina Jaffer, Darrell Belke, Nicole L. Rosin, Elodie Labit, Daniel Young, Friederike I. Schoettler, Keerthana Chockalingam, Benjamin Haeyul Lee, Jameson A. Dundas, Emilie de Chantal, Carmina A. Isidoro, Alexander Tam, Hanjoo B. Shim, Anna N. Zarzycki, Afshin Derakhshani, Elisabeth Gorgiogianni, Jeannine D. Turnbull, Antoine Dufour, Shalina S. Ousman, Jeff A. Biernaskie, Paul W.M. Fedak, Justin F. Deniset

×

Figure 5

FN1+ pericardial macrophages inhibit cardiac fibroblast activity via cystatin C.

Options: View larger image (or click on image) Download as PowerPoint
FN1+ pericardial macrophages inhibit cardiac fibroblast activity via cys...
(A and B) Schematic of in vitro coculture setup (A) and quantification of cardiac fibroblast–induced (CFb-induced) collagen gel contraction in response to TGF-β1 stimulation in the absence (CFb) or presence of enriched FN1+ pericardial macrophages or enriched pericardial T cells (B). n = 10 T cell–enriched patient pericardial samples; n = 13 FN1+ macrophage–enriched patient pericardial samples, and 13 independent experiments. **P < 0.01, 1-way ANOVA with Tukey’s multiple-comparison test. (C) Quantification of CFb-induced collagen gel contraction in response to TGF-β1 stimulation in the absence (CFb) or presence of direct or indirect (Transwell) pericardial macrophages (CD14+). n = 12 patient PF samples and 11 independent experiments. *P < 0.05; ****P < 0.0001, unpaired 2-tailed t test. (D) scRNA-seq quantification of top differentially expressed secreted factors in cluster 0 (FN1+) pericardial macrophages in either NOCAD or MI patients. (E) Schematic representation of IRF2 target sequence and RNA gene expression of its downstream activated gene, CST3, overlaid on the gene regulatory network clustering for pericardial macrophages. (F) Representative histogram plots of CST3 protein expression and quantification of isotype-normalized median fluorescence intensity in FN1+CD163hi and FN1–CD163lo human pericardial macrophages. *P < 0.05. (G) Quantification of CST3 release from conditioned medium of total human PFcs, human pericardial macrophages (CD14+), and pericardial T cells (CD3+). n = 16. ****P < 0.0001, 1-way ANOVA with Tukey’s multiple-comparison test. (H) Quantification of CST3 release from conditioned medium of human pericardial macrophages (CD14+) from NOCAD and MI patients. *P < 0.05. (I) Quantification of CFb-induced collagen gel contraction in response to TGF-β1 stimulation in the absence (CFb) or presence of PFc (CFb:PFc) with CST3 or isotype antibody blockade. n = 11 patient pericardial samples and 6 independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, 1-way ANOVA with Tukey’s multiple-comparison test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts